CytOSorb TreatMent Of Critically Ill PatientS Registry

NCT05146336 · tracked via the Priya Life Science Germany tracker

Sponsor

CytoSorbents, Inc

Phase

Observational

Started

2022-06-22

Last updated

2025-09-11

Condition(s) studied

Septic ShockAcute Respiratory Distress SyndromeTraumaRhabdomyolysisCardiogenic ShockPancreatitisAcute on Chronic Liver FailureAcute Liver FailureBurnsChimeric Antigen Receptor T-Cell Therapy (CAR-T) Cytokine Release Syndrome (CRS)Extracorporeal Life SupportPostoperative EndocarditisHemophagocytic LymphohistiocytosesLiver Transplant; ComplicationsInfectious DiseasePostoperative Vasoplegic SyndromeDrug OverdoseSepsis

Investigational drug(s) / intervention(s)

CytoSorb

CytoSorb: Sorbent hemoperfusion system

Study summary

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

Eligibility

Sex

ALL

Min age

—

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Planned OR actual CytoSorb® 300 mL device utilization 2. Informed consent for prospective registry participation Exclusion Criteria: 1. Use of the CytoSorb® 300 mL device for antithrombotic removal only 2. Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only 3. The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.

Primary outcome measure(s)

ICU mortality — Through ICU discharge or date of death, whichever comes first [on average 7 days]
In-hospital mortality — Through hospital discharge or date of death, whichever comes first [on average 14 days]

Trial sites (28)

Facility	City	Region	Status
Klinikum Klagenfurt am Wörthersee	Klagenfurt	Austria	Recruiting
Medizinische Universität Wien	Vienna	Austria	Recruiting
Universitätsklinikum Aachen	Aachen	Germany	Recruiting
Herz- und Diabeteszentrum Nordrhein-Westfalen	Bad Oeynhausen	Germany	Recruiting
Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil Bochum	Bochum	Germany	Recruiting
Katholisches Klinikum Bochum, St. Josef-Hospital	Bochum	Germany	Recruiting
Universitätsklinikum Essen, Medizinische Intensivtherapie	Essen	Germany	Recruiting
Universitätsklinikum Essen, Nephrologie	Essen	Germany	Recruiting
Universitätsklinikum Essen, Thorax- und Kardiovaskuläre Chirurgie	Essen	Germany	Recruiting
Universitätsmedizin Göttingen, Allgemein-, Viszeral- und Kinderchirurgie	Göttingen	Germany	Recruiting
Universitätsmedizin Göttingen, Herzzentrum Göttingen	Göttingen	Germany	Recruiting
Klinikum Herford	Herford	Germany	Recruiting
Universitätsklinikum Jena	Jena	Germany	Recruiting
Klinikum Kassel	Kassel	Germany	Withdrawn
Universitätsklinikum Marburg	Marburg	Germany	Recruiting
Kliniken Maria Hilf	Mönchengladbach	Germany	Terminated
Deutsches Herzzentrum München	München	Germany	Recruiting
LMU Klinikum München	München	Germany	Recruiting
Klinikum Oldenburg	Oldenburg	Germany	Recruiting
Helios Dr. Horst Schmidt Kliniken Wiesbaden	Wiesbaden	Germany	Recruiting
Ospedale Pediatrico Bambino Gesù	Roma	Italy	Terminated
IRCCS Ospedale Casa Sollievo della Sofferenza	San Giovanni Rotondo	Italy	Recruiting
SP ZOZ Szpital Uniwersytecki w Krakowie	Krakow	Poland	Recruiting
Uniwersyteckim Spitalem Klinicznym im. Jana Mikulicza - Radeckiego we Wrocławiu	Wroclaw	Poland	Recruiting
Unidade Local de Saúde de Coimbra E.P.E	Coimbra	Portugal	Recruiting
ULS São José, Hospital Curry Cabral	Lisbon	Portugal	Recruiting
Hospital Universitari Vall d'Hebron	Barcelona	Barcelona	Recruiting
Hospital Juan Ramón Jimenez	Huelva	Spain	Recruiting

More CytoSorbents, Inc trials in Germany

Safe and Timely Antithrombotic Removal (STAR) Registry Recruiting

Other trials for the same condition

A Study to Learn About How Safe BAY 3389934 is, Its Suitable Dose, and How it Affects the Participants With Sepsis Induced Coagulopathy Recruiting

Characterisation of phenotYpes in aCute Heart faiLure patiEnts Recruiting

Remote Ischemic Preconditioning in Septic Patients Recruiting

ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients Recruiting

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05146336 on ClinicalTrials.gov ↗ ← All trials in Germany